Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells 2,133 Shares of Stock

Key Points

• Insider sale: Jeffrey Farrow sold 2,133 shares of Tarsus at an average price of $68.71 on March 18 for about $146,558, reducing his stake by 4.48% to 45,502 shares (SEC Form 4 filed).
• Company performance and outlook: Tarsus beat revenue expectations ($151.7M vs. $144.6M) but missed on EPS (loss of $0.20 vs. $0.19 expected); analysts are mixed‑to‑favorable (average rating "Moderate Buy", average target ~$91.83) and institutional ownership is roughly 90%.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Jeffrey Farrow sold 2,133 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $68.71, for a total transaction of $146,558.43. Following the sale, the insider owned 45,502 shares of the company's stock, valued at approximately $3,126,442.42. The trade was a 4.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ:TARS traded down $1.49 during trading on Thursday, hitting $66.75. 461,600 shares of the stock were exchanged, compared to its average volume of 672,393. The company has a market cap of $2.84 billion, a PE ratio of -41.20 and a beta of 0.55. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.21. The company has a fifty day moving average price of $69.36 and a two-hundred day moving average price of $70.18. Tarsus Pharmaceuticals, Inc. has a 12-month low of $38.51 and a 12-month high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings data on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The firm had revenue of $151.67 million during the quarter, compared to analysts' expectations of $144.56 million. Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. On average, analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Key Headlines Impacting Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to "Strong‑Buy" and published a set of 2026 estimates that materially narrow expected losses (FY2026 now seen at -$1.01 vs. broader consensus -$3.17) and forecast a positive Q4‑2026 EPS of $0.09 — a clear bullish catalyst that can support upside expectations. Lifesci upgrade report
• Positive Sentiment: Large institutional investors have been increasing stakes (RTW, Deep Track, Jennison, Vanguard, Morgan Stanley among others), keeping roughly 90% institutional ownership — steady buying from big funds tends to support share-price stability and upside over time. MarketBeat TARS coverage
• Neutral Sentiment: Analyst consensus remains mixed‑to‑favorable: the average recommendation is "Moderate Buy" and some firms (Guggenheim, Oppenheimer) have raised targets while others are more cautious — this keeps the outlook constructive but not unanimous. Analyst consensus article
• Neutral Sentiment: Recent quarterly results: revenue beat estimates ($151.7M vs. $144.6M) but EPS slightly missed ($0.20 loss vs. $0.19 expected). Revenue strength is supportive; continued negative margins and guidance keep risk elevated until pipeline milestones materialize. Earnings summary
• Negative Sentiment: Insider selling: Director William J. Link sold 12,500 shares at an average $68.79 on March 16 (disclosed via SEC filing), reducing his stake by ~9.7%. Insider sales can create short‑term downward pressure or be interpreted by some investors as profit‑taking. InsiderTrades report (SEC Form 4)

Wall Street Analyst Weigh In

TARS has been the subject of a number of research reports. Lifesci Capital upgraded shares of Tarsus Pharmaceuticals to a "strong-buy" rating in a research report on Monday. The Goldman Sachs Group restated a "neutral" rating and set a $68.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Thursday, February 5th. Zacks Research lowered Tarsus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 25th. Wall Street Zen downgraded Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, February 28th. Finally, Oppenheimer boosted their price target on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the stock an "outperform" rating in a report on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $91.83.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Tarsus Pharmaceuticals by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,143 shares of the company's stock worth $1,137,000 after acquiring an additional 1,217 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Tarsus Pharmaceuticals by 2.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,220 shares of the company's stock worth $3,659,000 after buying an additional 1,394 shares during the period. Jane Street Group LLC lifted its position in Tarsus Pharmaceuticals by 105.8% during the first quarter. Jane Street Group LLC now owns 10,456 shares of the company's stock worth $537,000 after buying an additional 190,000 shares during the period. Envestnet Asset Management Inc. boosted its stake in Tarsus Pharmaceuticals by 15.9% in the 2nd quarter. Envestnet Asset Management Inc. now owns 10,356 shares of the company's stock worth $420,000 after buying an additional 1,418 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Tarsus Pharmaceuticals by 8.0% in the 2nd quarter. Geode Capital Management LLC now owns 934,420 shares of the company's stock worth $37,859,000 after buying an additional 68,986 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company's stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.